Wird geladen...
INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
Much attention has been recently paid to the study of interleukin 6 (IL-6) among the cytokines involved in the development of immune inflammatory rheumatic diseases (IIRDs). The introduction of monoclonal antibodies that inhibit the activity of IL-6 (tocilizumab, TCZ) in clinical practice in 2010 is...
Gespeichert in:
Hauptverfasser: | , |
---|---|
Format: | Artigo |
Sprache: | Russo |
Veröffentlicht: |
IMA-PRESS LLC
2018-01-01
|
Schriftenreihe: | Научно-практическая ревматология |
Schlagworte: | |
Online Zugang: | https://rsp.mediar-press.net/rsp/article/view/2461 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|